Repligen Corporation (RGEN)
Repligen: A Buy As Its Growth Engine Gears Up
Repligen demonstrates 13% organic growth despite Filtration headwinds, with strong momentum in the Proteins and Process Analytics segments. Filtration's drag is temporary, with mid-single-digit growth expected in 2026 and order activity fueling a robust 2027 backlog. The BioLife acquisition adds high-margin, sticky cell therapy consumables, with anticipated synergies and accretive EPS contributions post-closing.
BioLife Solutions Shareholders Approve Repligen Merger Agreement
BioLife Solutions NASDAQ: BLFS stockholders approved the company's merger agreement with Repligen Corporation at a special meeting held virtually on Oct. 5, 2026, clearing a key shareholder-vote requirement for the proposed transaction.
Repligen Corporation (RGEN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Repligen Corporation (RGEN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Why Is Repligen (RGEN) Up 27.7% Since Last Earnings Report?
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.
Wall Street Analysts Believe Repligen (RGEN) Could Rally 25.72%: Here's is How to Trade
The consensus price target hints at a 25.7% upside potential for Repligen (RGEN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Repligen Beats Q2 Earnings Estimates, Raises 2026 View, Stock Up
RGEN tops Q2 earnings and revenue estimates, lifts its 2026 revenue and EPS outlook, and sees shares jump after stronger-than-expected results.
Repligen Q2 Earnings Call Highlights
Repligen NASDAQ: RGEN reported second-quarter 2026 revenue of $204 million, up 12% year over year on a reported basis and 13% organically, as demand for proteins, analytics products and recurring consumables supported growth. The company also raised its full-year organic revenue growth and adjusted earnings outlook, citing continued order momentum and improved visibility into the second half.
Repligen (RGEN) Beats Q2 Earnings and Revenue Estimates
Repligen (RGEN) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.37 per share a year ago.
Repligen to Expand Cell Therapy Capabilities With BioLife Buyout
RGEN's $1.5 billion BioLife acquisition aims to expand its cell therapy capabilities, adding biopreservation products and expected revenue and EPS benefits.
Repligen Corporation (RGEN) M&A Call Transcript
Repligen Corporation (RGEN) M&A Call Transcript
Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reach
Repligen NASDAQ: RGEN said it has signed a definitive agreement to acquire BioLife Solutions in a transaction valued at approximately $1.5 billion, adding a cell therapy-focused platform that management said will expand Repligen's exposure to one of the faster-growing areas of bioprocessing.
